š”š²šš š¦ššŗšŗš®šæš
ā¢ Zydus Lifesciences has received final approval from the US FDA for its heart drug Ivabradine, which reduces the risk of hospitalisation for worsening heart failure in adult patients.
ā¢ The company may be eligible for 180 days of shared generic exclusivity for the drug.
ā¢ The stock has gained 52.5% this year against Nifty's 11.42% rise.